Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Item

http://www.wikidata.org/entity/Q30381713

Q30381713

about

Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling Vaccines for preventing influenza in healthy adults Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.Clinical vaccine development for H5N1 influenza.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.An evaluation of the emerging vaccines against influenza in children.Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines.Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial Inactivated influenza vaccines: recent progress and implications for the elderly.Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.MF59 adjuvant: the best insurance against influenza strain diversity.Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Influenza vaccination for older adults.The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country.Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

P2860

Q21131780-55CEB743-DD1E-4377-8FD5-BEB7E2404DBE Q24197955-71959513-7D62-4046-8B77-AB3A4DFAA1EA Q28751886-6FD8B518-C659-448E-A6CE-49A76CCA3E7E Q30209583-66F95CFF-ED51-47BE-97F8-51C9B9143A06 Q30222083-615CC03D-6FB9-4085-B065-FA8A68EB5E7B Q30352329-8E78B199-2EAF-4CE3-9951-3290907B4006 Q30359243-73C0086F-EA2A-4200-A17E-88FBC8C28152 Q30359375-C25946F5-0053-4E50-BDD5-064411ECA953 Q30360190-C0B5E3F3-8A04-4158-B374-65ED5E18974E Q30362883-79A8558A-5A3E-4500-9444-CD281C74610D Q30367603-3FD3CA4F-4BEC-4D62-B1E1-53FD09939413 Q30368645-BC2C512F-E680-4B00-8BFA-1F0890F541B5 Q30369467-188D0AB5-04F5-4CDD-84A2-44AA28E91D6C Q30372260-BB19A7AF-D318-48A0-A0F8-6D9BE9B36B90 Q30381280-3A9BA6BB-EC56-43F4-B4D2-0FEA14BBA7FD Q30385570-9D7B4C7D-53B2-48D9-8745-B365498E7ABB Q30388996-77DBBCE7-CD81-432C-8026-5EE8980193E7 Q30394896-40D8D52A-F94C-4B90-A7CC-073CBE622B7A Q30396654-477E0036-695D-4311-B9AB-70502734F3B7 Q30397257-726C560A-38FA-42E2-9ECD-EE92A5187A37 Q30397652-A3CFA842-AE09-4800-9A45-54F8D97FC987 Q30399057-0468EC7B-9D2E-4BA9-BF6A-0284F6F81116 Q30401304-AC5C98B8-9DB0-4A3A-99AA-A0AC20E946D2 Q30402018-76DA97CB-5FD5-42D9-9F7C-FBFF7891A69F Q30403078-FD4633F4-2BDC-44B7-954D-9EE004CB97D4 Q30407424-65A4A69E-C685-4C63-A18B-6CD13AA164CF Q30413695-5A6AD004-63F9-430F-948E-3B329D26E26C Q30419062-22F67A2A-AE37-4CCF-8E8C-5F25EB7EF7A2 Q30419842-F49217D1-2DC2-431F-B1D2-941A3EAD44B9 Q30420397-20200621-62EB-4364-A5FB-088AFCDD9223 Q30427591-3BA0B0B3-5BDB-4131-893B-66A4509EEDAB Q30429185-BEC908B0-4DD4-409D-892B-5ED5DDFDCB60 Q33793770-A40FC25E-D443-4D77-AA8A-045C2154BAE1 Q33815195-D5E3CBC9-50A5-4AFD-9D1E-5D2FBFED79DD Q33939303-AEF93AC1-CA71-41B2-AEC8-D2375ED93D9B Q34247732-0097F40F-431C-4D79-9237-1C27440D2F21 Q34500175-C9B040D1-1E58-4299-B0E3-7394C14799AF Q34903425-E8CF3B52-D24E-44D2-8F53-961004819342 Q35100779-D8D005C4-BA81-41C0-B37C-F4BFE6E3BFFB Q35272502-65125094-0F0F-40EE-ACFA-D4EAD27674D8

P2860

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Item

http://www.wikidata.org/entity/Q30381713

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu